Biodribin is a medicine used in antineoplastic therapy. It contains cladribine – a compound which acts as a purine analogue (which participates in the synthesis of nucleic acids). Appropriate doses are administered by long-lasting intravenous infusion.

Cladribine is toxic to lymphocytes undergoing neoplastic changes. After intravenous injection, the drug quickly enters neoplastic cells and kills them by inhibiting the activity of a number of enzymes responsible for cell metabolism, as well as inhibiting cell cycle progression. Biodribin is intended for treatment of haematopoietic system neoplasms: hairy cell leukaemia (HCL) at any stage of the disease, chronic lymphocytic leukaemia (CLL) and low grade non-Hodgkin's lymphoma (LG NHL) in primary or secondary resistance to other cytostatic therapies.